<div id="readability-page-1"><div><h2>FDA approval for repeat iDose TR use puts Glaukos (GKOS) back in focus</h2> <p>Glaukos (GKOS) is back on investors’ radar after the U.S. FDA approved a labeling supplement for repeat administration of its iDose TR glaucoma therapy, expanding potential real world treatment flexibility for physicians.</p> <p>See our latest analysis for Glaukos.</p> <p>At a share price of $113.27, Glaukos has seen a 26.01% 90 day share price return, while its 1 year total shareholder return of 24.49% decline contrasts with a 125.37% total shareholder return over three years. This suggests that longer term momentum has been stronger than the recent pullback as investors weigh the iDose TR label expansion against prior gains.</p> <p>If this glaucoma news has you thinking more broadly about eye care and medical technology, it could be a good time to scan 26 healthcare AI stocks for other potential ideas in the healthcare space.</p> <p>With iDose TR now cleared for repeat use and Glaukos still reporting losses on US$469.82 million in revenue, the key question is simple: are you looking at an underappreciated growth story or a stock where the market is already pricing in future gains?</p> <h2>Most Popular Narrative: 14.7% Undervalued</h2> <p>At $113.27, the most followed narrative for Glaukos points to a fair value of $132.71 based on detailed cash flow and profitability assumptions using a 7.67% discount rate.</p> <blockquote> <p><em>Glaukos' pipeline diversification into corneal health (Epioxa approval expected in late 2025/early 2026), novel glaucoma devices, and early-stage retinal programs positions the company to benefit from increased diagnostic rates and expanding access to ophthalmic interventions globally, providing avenues for future top-line growth and risk mitigation against single-product dependency.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Curious what has to happen across glaucoma, corneal, and retinal franchises to support that higher fair value? The narrative leans on faster revenue expansion, a sharp turn in margins, and a future earnings multiple that is well above typical medical equipment names. Want to see exactly which assumptions carry the most weight in that story?</p> <p><strong>Result: Fair Value of $132.71 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this hinges on Glaukos executing in a competitive glaucoma market, while managing reimbursement and regulatory setbacks that could delay or dilute the expected payoff.</p> <p>Find out about the key risks to this Glaukos narrative.</p> <h2>Another Angle on Valuation</h2> <p>Our DCF work presents a very different picture. At $113.27, Glaukos is trading about 60.7% below the SWS DCF model estimate of $287.96 per share, which also identifies the stock as undervalued. When one model indicates modest upside and another points to a much larger gap, the key question becomes: which set of assumptions do you find more reasonable?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e612017b-7a6e-4ed6-9c5d-d6b5c57650dd/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e612017b-7a6e-4ed6-9c5d-d6b5c57650dd/chart/dcf"/><figcaption>GKOS Discounted Cash Flow as at Feb 2026</figcaption></figure><h2> Build Your Own Glaukos Narrative</h2> <p>If you are not fully convinced by these assumptions or prefer to rely on your own work, you can test the data yourself and Do it your way in just a few minutes.</p> <p>A great starting point for your Glaukos research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</p> <h2>Looking for more investment ideas?</h2> <p>If Glaukos has caught your attention but you do not want to stop at one name, this is the moment to widen your net and pressure test your thinking with fresh ideas.</p> <ul> <li>Target potential mispricings by scanning companies that look attractively valued on fundamentals using our 52 high quality undervalued stocks built from clear, transparent criteria.</li> <li>Prioritise resilience by focusing on businesses with robust finances through the solid balance sheet and fundamentals stocks screener (45 results), so you are not relying on hope when conditions get tougher.</li> <li>Hunt for less crowded opportunities by reviewing our screener containing 24 high quality undiscovered gems, where smaller, underfollowed companies with solid fundamentals might be flying under the radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

GKOS

<p>Glaukos (GKOS) has gained attention following FDA approval for repeat use of its iDose TR glaucoma therapy. The stock is currently priced at $113.27, reflecting a 26.01% return over 90 days, but a 24.49% decline over the past year. Analysts suggest a fair value of $132.71, indicating it may be undervalued. However, a DCF model estimates a much higher fair value of $287.96. The company's future growth depends on successful execution in a competitive market and managing potential risks.</p>

Assessing Glaukos (GKOS) Valuation After FDA Clearance For Repeat Use Of iDose TR